Showcase Your Work
Applications are now open for this year's poster session. This is an exclusive opportunity to share what you are currently working on, allowing you to:
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of biopharma experts eager to hear the latest cell engager innovations, you will have the opportunity to display a poster presenting your own research. Don’t miss out on the chance to connect, learn, and present.
- Demonstrate your thought leadership in this dynamic field
- Gain visibility and exposure in showcasing your innovations
- Engage in meaningful discussions with industry peers to receive direct feedback
- Attract the attention of industry stakeholders and collaborators
How to Submit Your Poster
How to Submit Your Poster
- You must first register your place to attend the T-Cell Engager Therapeutics Summit Europe
- Submit an abstract for review to showcase your poster during the Scientific Poster Session
- You will be notified once your abstract has been accepted along with details of printing and size requirements. We do request an online PDF of the poster 2 weeks prior to the summit
- Scientific Poster Session: 10 December 2025
- Abstract Submission Deadline: 28 November 2025
Explore the Full Event Guide
- Benchmark the latest clinical and preclinical insights shaping next-generation TCE development in oncology and autoimmunity
- Translate innovative design strategies, from co-stimulation to masked and logic-gated TCEs into improved specificity, potency, and safety
- Equip yourself with solutions to overcome translational and preclinical challenges, including hyperactivated T cells and unrealistic tumour clearance models
- Connect with leading biopharma, biotech, and academic pioneers driving novel modalities such as TITAN nanobodies, MAIT engagers, and NK cell engagers
- Position your team at the forefront of emerging therapeutic opportunities, with firsthand insights into investment trends, partnerships, and expansion into autoimmune disease
